药物信息为Vagifem (estradiol vaginal tablets) Initial U.S. Approval: 1999 (Novo Nordisk): 7 DRUG INTERACTIONS
- WARNING: CARDIOVASCULAR DISORDERS, ENDOMETRIAL CANCER, BREAST CANCER and PROBABLE DEMENTIA
- 3 DOSAGE FORMS AND STRENGTHS
- 4 CONTRAINDICATIONS
- 6 ADVERSE REACTIONS
- 7 DRUG INTERACTIONS
- 10 OVERDOSAGE
- 11 DESCRIPTION
- 15 REFERENCES
- 17 PATIENT COUNSELING INFORMATION
- 17.5 FDA-Approved Patient Labeling
- Principal Display panel - VAGIFEM 25 µg
- Principal Display panel - VAGIFEM 10 µg
- 外部链接相关的Vagifem (estradiol vaginal tablets) Initial U.S. Approval: 1999 (Novo Nordisk)
No drug- drug interaction studies have been conducted with Vagifem.
7.1 Metabolic Interactions
In-vitro and in-vivo studies have shown that estrogens are metabolized partially by cytochrome P450 3A4 (CYP3A4). Therefore, inducers or inhibitors of CYP3A4 may affect estrogen drug metabolism. Inducers of CYP3A4, such as St. John's Wort (Hypericum perforatum) preparations, phenobarbital, carbamazepine, and rifampin, may reduce plasma concentrations of estrogens, possibly resulting in a decrease in therapeutic effects and/or changes in the uterine bleeding profile. Inhibitors of CYP3A4 such as erythromycin, clarithromycin, ketoconazole, itraconazole, ritonavir and grapefruit juice may increase plasma concentrations of estrogens and may result in side effects.
- Drug Information Provided by National Library of Medicine (NLM).